Mitochondrial DNA Mutations and Mitochondrial Abnormalities in Dilated Cardiomyopathy |
| |
| Authors: | Eloisa Arbustini, Marta Diegoli, Roberta Fasani, Maurizia Grasso, Patrizia Morbini, Nadia Banchieri, Ornella Bellini, Barbara Dal Bello, Andrea Pilotto, Giulia Magrini, Carlo Campana, Paolo Fortina, Antonello Gavazzi, Jagat Narula, Mario Vigan |
| |
| Affiliation: | Eloisa Arbustini, Marta Diegoli, Roberta Fasani, Maurizia Grasso, Patrizia Morbini, Nadia Banchieri, Ornella Bellini, Barbara Dal Bello, Andrea Pilotto, Giulia Magrini, Carlo Campana, Paolo Fortina, Antonello Gavazzi, Jagat Narula, and Mario Viganò |
| |
| Abstract: | Mitochondrial (mt)DNA defects, both deletions and tRNA point mutations, have been associated with cardiomyopathies. The aim of the study was to determine the prevalence of pathological mtDNA mutations and to assess associated defects of mitochondrial enzyme activity in dilated cardiomyopathy (DCM) patients with ultrastructural abnormalities of cardiac mitochondria. In a large cohort of 601 DCM patients we performed conventional light and electron microscopy on endomyocardial biopsy samples. Cases with giant organelles, angulated, tubular, and concentric cristae, and crystalloid or osmiophilic inclusion bodies were selected for mtDNA analysis. Mutation screening techniques, automated DNA sequencing, restriction enzyme digestion, and densitometric assays were performed to identify mtDNA mutations, assess heteroplasmy, and quantify the amount of mutant in myocardial and blood DNA. Of 601 patients (16 to 63 years; mean, 43.5 ± 12.7 years), 85 had ultrastructural evidence of giant organelles, with abnormal cristae and inclusion bodies; 19 of 85 (22.35%) had heteroplasmic mtDNA mutations (9 tRNA, 5 rRNA, and 4 missense, one in two patients) that were not found in 111 normal controls and in 32 DCM patients without the above ultrastructural mitochondrial abnormalities. In all cases, the amount of mutant was higher in heart than in blood. In hearts of patients that later underwent transplantation, cytochrome c oxidase (Cox) activity was significantly lower in cases with mutations than in those without or controls (P = 0.0008). NADH dehydrogenase activity was only slightly reduced in cases with mutations (P = 0.0388), whereas succinic dehydrogenase activity did not significantly differ between DCM patients with mtDNA mutations and those without or controls. The present study represents the first attempt to detect a morphological, easily identifiable marker to guide mtDNA mutation screening. Pathological mtDNA mutations are associated with ultrastructurally abnormal mitochondria, and reduced Cox activity in a small subgroup of non-otherwise-defined, idiopathic DCMs, in which mtDNA defects may constitute the basis for, or contribute to, the development of congestive heart failure. |
| |
| Keywords: | |
|
|
